Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population

Journal of Managed Care Pharmacy

Volumn 14, Issue 9, 2008, Pages 844-857

  Kruse, Gregory B ^a   Amonkar, Mayur M ^b   Smith, Gregory ^b   Skonieczny, Dean C ^c   Stavrakas, Spyros ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Medical Present Value Inc   (United States)

^d Market Strategies Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GRANISETRON; HEPARIN; IRINOTECAN; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PALONOSETRON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; DRUG COST; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MEDICAL FEE; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; OFF LABEL DRUG USE; PAIN; POPULATION RESEARCH; PRACTICE GUIDELINE; SINGLE DRUG DOSE; UNITED STATES;

EID: 57749102532     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.9.844     Document Type: Article

References (23)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008. Available at: www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf. Accessed September 15, 2008.
2. In 2004 dollars, as reported in Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care. 2002;40(Suppl 8):IV-104-17.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
4. National Comprehensive Cancer Networks. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2008). National Comprehensive Cancer Network, Inc., 2008. Available at: www.nccn.org. Accessed August 20, 2008.
5. Sharma S, Saltz LB. Oral chemotherapeutic agents for colorectal cancer. Oncologist. 2000;5:99-107.
6. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87:933-37.
7. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 2001;6(Suppl 4):12-16.
8. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998;16:2557-67.
9. Batlle, JF. Arranz EE., de Castro Carpeno, J., et al. Oral chemotherapy: potential benefits and limitations. Clin Transl Oncol. 2004;6:335-40. Available at: www.springerlink.com/content/ 8p000g35554xq621/Accessed October 9, 2008.
10. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Finance Rev. 1997;18:51-76.
11. Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med. 1996;156:2197-201.
12. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Ins. 1995;87(6):417-26.
13. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25-32.
14. Bach PB. Costs of cancer care: a view from the Centers for Medicare and Medicaid Services. J Clin Oncol. 2007;25:18700.
15. Duh MS, Weiner JR, Lefebvre P, Neary MP, Skarin AT. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: A retrospective claims database analysis. Curr Med Res Opin. 2008;24(4):967-74.
16. Kruse GB, Amonkar MM, Skonieczny D, Smith GL. An analysis of costs associated with administration of trastuzumab-based combination IV therapies in metastatic breast cancer patients in a U.S. population. Poster presented at: 2007 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; May 19-23, 2007; Arlington, VA.
17. Kruse GB, Amonkar MM, Skonieczny D, Smith GL. Costs of administration of intravenous (IV) therapies in early versus late-stage breast cancer in a U.S. population. Poster presented at: 2007 American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.
18. Giuliani G, Falcone A, Garrison L. Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting. Poster presented at: 2007 American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.
19. Pashko S, Johnson DM. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer. Pharmacoeconomics. 1992;1(4):293-97.
20. Fallowfield L, Atkins L, Chit S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205-10.
21. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-15.
22. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239-45.
23. Gornas M, Szczylik C. Oral treatment of metastatic breast cancer (MBC) with capecitabine (X): What influences the decision-making process? Poster presented at: 2007 American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.